Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.
Normally, IMM-124E is used to manufacture the company’s flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn.
Overall, the preliminary data set Immuron has generated potentially offers a new oral therapeutic approach to target and directly inhibit the virus in the gastrointestinal tract and warrants further evaluation to identify the inhibitory substances in the company’s products, at least according to management.
In terms of the study, the in-vitro susceptibility of the virus to IMM-124E was determined using the quantitative assay that measures virus replication in the presence of increasing concentrations of the product compared to replication in the absence of the product. The effective concentration of IMM-124E was reported as the concentration of the product at which virus replication is inhibited by 50% or 90%.
Another major finding made during the study was that cell viability in the presence of IMM-124E was greatly enhanced when compared to placebo. IMM-124E improved cell viability by 180% to 260% relative to controls. These results indicate that IMM-124E at concentrations that inhibited SARSCoV-2 replication improved cell viability.
Looking forward, the company has filed a provisional patent application in respect of the findings.
Immuron stock closed Monday up over 63% at $10.41, in a 52-week range of $1.55 to $28.99. The consensus price target is $8.56. Following the announcement, the stock was up another 114% at $22.29 in early trading indications on Tuesday.
24/7 Wall St.The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.